Pfizer Inc. $PFE Shares Sold by Sigma Planning Corp

Sigma Planning Corp cut its position in Pfizer Inc. (NYSE:PFE) by 7.9% during the second quarter, HoldingsChannel.com reports. The fund owned 165,925 shares of the biopharmaceutical company’s stock after selling 14,167 shares during the period. Sigma Planning Corp’s holdings in Pfizer were worth $4,022,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Capital Advisors Inc. OK boosted its stake in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after buying an additional 17,032 shares during the last quarter. Westbourne Investments Inc. purchased a new stake in Pfizer in the first quarter valued at $2,411,000. Bourne Lent Asset Management Inc. raised its position in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Strs Ohio purchased a new stake in Pfizer in the first quarter valued at $49,968,000. Finally, IFM Investors Pty Ltd raised its position in Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after purchasing an additional 41,263 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $28.24.

Pfizer Price Performance

PFE stock opened at $24.69 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $140.40 billion, a PE ratio of 13.14, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.14. The business’s fifty day moving average price is $24.76 and its 200 day moving average price is $24.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.